Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

Trial Details

NCT ID

NCT06800313

Phase

PHASE1 / PHASE2

Sponsor

Janssen Research & Development, LLC

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• JNJ-101556143 Formulation 1
• JNJ-101556143 Formulation 2
• JNJ-101556143 Formulation 3

Locations (sample)

• Colorado Springs, Colorado, United States|38.83388,-104.82136
• Denver, Colorado, United States|39.73915,-104.9847
• New Haven, Connecticut, United States|41.30815,-72.92816
• Sarasota, Florida, United States|27.33643,-82.53065
• Metairie, Louisiana, United States|29.98409,-90.15285

Key Eligibility Criteria

• All Study Arms (Phase 1 Part 1 \& 2, Phase 2 Part 1, Part 2A, 2B, 2C \& 2D):
• Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepa…
• mCRPC Arms: (Phase 1 Part 1 \& 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testoste…
• SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next genera…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.